Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Etiologic analysis of Chinese patients with agranulocytosis and hematopathies infected with resistant bacteria: Anti-bacterial effect of tigecycline

Feifei Che , Chunqian Wan, Xiaodong Wang, Jiao Chen, Juan Huang

Department of Hematology, Sichuan Academy of Medical Science and Sichuan Peopleâ€™s Hospital, Chengdu, 610072, China;

For correspondence:- Feifei Che Email: feifeiche@cntv.cn Tel:+862887732855

Accepted: 17 June 2018 Published: 28 July 2018

Citation: Che F, Wan C, Wang X, Chen J, Huang J. Etiologic analysis of Chinese patients with agranulocytosis and hematopathies infected with resistant bacteria: Anti-bacterial effect of tigecycline. Trop J Pharm Res 2018; 17(7):1407-1413 doi: 10.4314/tjpr.v17i7.26

© 2018 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To assess the etiologic characteristics of resistant bacterial infections occurring in agranulocytosis patients with hematopathies, and to determine the effect of tigecycline (TGC).

Methods: After ineffective treatment with carbapenem, all of the patients were divided into the following three groups: TGC alone (15 cases); TGC as initial treatment, followed by a combination with other antibiotics (40 cases); and TGC in combination with other antibiotics from the start of treatment (71 cases).

Results: Among the 126 patients, 108 had fevers (85.71 %). The most common infection site was lung, accounting for 71.43 % of all infections. A total of 52 pathogens were isolated from 126 hospitalized patients, including 38 Gram-negative bacteria (70.37 %), 14 Gram-positive bacteria (25.93 %), and 2 fungi (3.70 %). TGC treatment efficacy was 50.79 %. There were no statistically significant differences between the three treatment groups (p = 0.473). Adverse drug reaction was nausea and vomiting (14.29 %), nausea without vomiting (11.90 %), diarrhea (6.35 %), and generalized skin rash with itching (3.17 %).

Conclusion: TGC is effective in treating neutropenic patients with hematopathies who are infected with resistant bacteria. The side effects of TGC are few; thus, TGC is safe and generally well-tolerated.

Keywords: Tigecycline, Agranulocytosis, Resistant bacteria, Hematopathy, Neutropenic patients